COVID-19

[NPJ Vaccines] Scientists developed a prototype two-dose vaccine by combining the Receptor Binding Domain antigen, via conjugation to Diphtheria toxoid.

[Science Immunology] The authors used rhesus macaques to model protective primary immune responses in tissues during mild COVID-19.

[Aeterna Zentaris, Inc.] Aeterna Zentaris, Inc. announced it has expanded the scope of its existing research program with the Julius-Maximilians-University Wuerzburg, on the development of COVID-19 and Chlamydia trachomatis vaccines.

[Stem Cell Research & Therapy] A prospective randomized double-blind placebo-controlled clinical trial assessed the safety and efficacy of secretome derived from allogeneic menstrual blood stromal cells as a treatment in patients with severe COVID-19.

[Science] CD8+ T expressing inhibitory killer cell immunoglobulin-like receptors cells efficiently eliminated pathogenic gliadin-specific CD4+ T cells from celiac disease patients’ leukocytes in vitro.

[Journal of Clinical Microbiology] Investigators discuss what Correlates of Protections are, review the current understanding of infection-induced, vaccine-elicited and hybrid immunity to COVID-19 and summarize the current and potential future utility of SARS-CoV-2 serologic testing.